Key result
Trastuzumab biosimilar SB3 reduces event-free survival events ~53% versus reference trastuzumab in HER2-positive breast cancer.
Why the study?
Long-term cardiac safety and efficacy data comparing trastuzumab biosimilar SB3 with reference trastuzumab in HER2-positive early breast cancer were needed.
Does a trastuzumab biosimilar (SB3) have comparable long-term cardiac safety and efficacy to reference trastuzumab in patients with HER2-positive early breast cancer?
RCT (n=367)
Does a trastuzumab biosimilar (SB3) have comparable long-term cardiac safety and efficacy to reference trastuzumab in patients with HER2-positive early breast cancer?
Long-term follow-up demonstrates that the trastuzumab biosimilar SB3 has rare cardiotoxicity and higher event-free survival compared to reference trastuzumab in HER2-positive early breast cancer.
Answers are grounded in this paper and cite their sources.
SB3 was associated with fewer EFS events; leaves open long-term cardiac safety equivalence versus reference trastuzumab in HER2-positive breast cancer.
BACKGROUND: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study. METHODS: Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox proportional hazards regression model was used to assess factors associated with EFS. RESULTS: A total of 367 patients were enrolled in the study (SB3, n = 186; TRZ, n = 181). The median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3 and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of asymptomatic significant LVEF decrease was rare (SB3, n = 1; TRZ, n = 2), with all patients recovering with LVEF ≥ 50%, and no cases of symptomatic CHF or other cardiac events were reported. At 3 years, the EFS was 91.9% with SB3 and 85.2% with TRZ. The number of patients with events was 17 (9.1%) with SB3 and 31 (17.1%) with TRZ [hazard ratio: 0.47, 95% confidence interval: 0.26-0.87]. Antibody-dependent cell-mediated cytotoxicity (ADCC) activity and the breast pathologic complete response rate were the factors associated with EFS. CONCLUSION: Cardiotoxicity was rare in this extension study. EFS was higher with SB3 versus TRZ, with post hoc analysis suggesting that a downward drift in ADCC activity was a contributing factor. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02771795 (EudraCT 2015-005663-17).
No takes yet. Share an insight, caveat, or question.
Pivot et al. (2019) conducted an RCT in human epidermal growth factor receptor 2-positive early breast cancer (n=367). SB3 (trastuzumab biosimilar) vs. reference trastuzumab (TRZ) was evaluated on Event-free survival (EFS) events (HR 0.47, 95% CI 0.26-0.87). The trastuzumab biosimilar SB3 reduced event-free survival events compared to reference trastuzumab in patients with HER2-positive early breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: